Latest news with #Fisher&PaykelHealthcareCorporationLimited
Business Insider
4 days ago
- Business
- Business Insider
Citi upgrades Fisher & Paykel Healthcare Corporation Limited (FSPKF) to a Hold
Fisher & Paykel Healthcare Corporation Limited (FSPKF – Research Report) received a Hold rating and price target from Citi analyst Mathieu Chevrier today. The company's shares closed last Thursday at $20.70. Confident Investing Starts Here: According to TipRanks, Chevrier is an analyst with an average return of -5.4% and a 40.30% success rate. Chevrier covers the Healthcare sector, focusing on stocks such as Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per Cochlear , and EBOS Group Limited. In addition to Citi, Fisher & Paykel Healthcare Corporation Limited also received a Hold from UBS's Marcus Curley in a report issued on May 29. However, on May 30, Morgan Stanley upgraded Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) to a Buy. Based on Fisher & Paykel Healthcare Corporation Limited's latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $951.2 million and a net profit of $153.2 million. In comparison, last year the company earned a revenue of $815.8 million and had a net profit of $107.3 million
Business Insider
29-05-2025
- Business
- Business Insider
Fisher & Paykel Healthcare Corporation Limited (FSPKF) was downgraded to a Hold Rating at UBS
Fisher & Paykel Healthcare Corporation Limited (FSPKF – Research Report) received a Hold rating and price target from UBS analyst Marcus Curley today. The company's shares closed last Thursday at $20.70. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Curley is ranked #9118 out of 9551 analysts. In addition to UBS, Fisher & Paykel Healthcare Corporation Limited also received a Hold from Morgan Stanley's David Bailey in a report issued on May 27. However, yesterday, Jefferies upgraded Fisher & Paykel Healthcare Corporation Limited (Other OTC: FSPKF) to a Buy.
Business Insider
25-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Vigil Neuroscience Inc (VIGL), Fisher & Paykel Healthcare Corporation Limited (OtherFSPKF) and Viridian Therapeutics (VRDN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vigil Neuroscience Inc (VIGL – Research Report), Fisher & Paykel Healthcare Corporation Limited (FSPKF – Research Report) and Viridian Therapeutics (VRDN – Research Report). Confident Investing Starts Here: Vigil Neuroscience Inc (VIGL) In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Vigil Neuroscience Inc, with a price target of $11.00. The company's shares closed last Friday at $7.89. According to Matteis is a 3-star analyst with an average return of 1.2% and a 40.9% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Neumora Therapeutics, Inc., Sionna Therapeutics, Inc., and KalVista Pharmaceuticals. Vigil Neuroscience Inc has an analyst consensus of Hold, with a price target consensus of $9.50. Fisher & Paykel Healthcare Corporation Limited received a Hold rating and a A$35.80 price target from Jefferies analyst Vanessa Thomson on May 23. The company's shares closed last Thursday at $20.70. Thomson has an average return of 22.2% when recommending Fisher & Paykel Healthcare Corporation Limited. According to Thomson is ranked #1098 out of 9562 analysts. Currently, the analyst consensus on Fisher & Paykel Healthcare Corporation Limited is a Moderate Buy with an average price target of $25.30. Viridian Therapeutics (VRDN) Stifel Nicolaus analyst Alex Thompson CFA maintained a Buy rating on Viridian Therapeutics today and set a price target of $41.00. The company's shares closed last Friday at $13.57, close to its 52-week low of $11.40. According to CFA 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -5.8% and a 40.7% success rate. CFA covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Crinetics Pharmaceuticals, and Third Harmonic Bio, Inc. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Viridian Therapeutics with a $38.80 average price target, representing a 189.8% upside. In a report issued on May 20, Wedbush also maintained a Buy rating on the stock with a $41.00 price target.
Business Insider
20-05-2025
- Business
- Business Insider
UBS Remains a Buy on Fisher & Paykel Healthcare Corporation Limited (FSPKF)
UBS analyst Marcus Curley maintained a Buy rating on Fisher & Paykel Healthcare Corporation Limited (FSPKF – Research Report) today. The company's shares closed last Thursday at $20.70. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter According to TipRanks, Curley is an analyst with an average return of -12.5% and a 44.16% success rate. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Fisher & Paykel Healthcare Corporation Limited with a $24.95 average price target. FSPKF market cap is currently $12.8B and has a P/E ratio of 111.53. Based on the recent corporate insider activity of 28 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of FSPKF in relation to earlier this year.
